Answers are grounded in this paper and cite their sources.
About 50% of newly diagnosed mutilple myeloma (MM) patients (NDMM) have some degree of renal impairment (RI) at presentation, up to 20% have severe acute kidney injury (AKI) and ~1–5% may require extrarenal dialysis, whereas severe RI is associated with high risk of early death and other complications. 1 , 2 Immediate effective anti-myeloma therapy and vigorous supportive care are the cornerstones of management. 2 , 3 However, there are limited data focusing specifically on the management and outcomes of MM patients requiring dialysis as a consequence of MM, mostly including small numbers of patients on dialysis. 4 , 5 , 6 , 7 , 8 Moreover, the use of high cut-off hemodialysis to rapidly reduce the load of nephrotoxic light chains may provide some additional benefit in patients requiring dialysis when treated with bortezomib-based therapies, but the reported results of two randomized studies are controversial. 9 , 10 Thus, we analyzed the outcomes of 52 consecutive NDMM with RI requiring dialysis, which were managed and treated in a single center, to provide data on response to therapy, dialysis discontinuation and survival in unselected patients, outside the context of clinical trials.
No takes yet. Share an insight, caveat, or question.
Dimopoulos et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: